OMass Raises $310 Million for Endocrine and Immune Programs

Company OMass Therapeutics Event Type Financing (Series C) Modality Small molecule; native mass spectrometry platform (OdyssION) for membrane proteins and complexes Asset OMS1620 (MC2R antagonist); SLC15A4 inhibitor Target MC2R; SLC15A4 Disease Area Congenital adrenal hyperplasia; ACTH-dependent Cushing syndrome; systemic lupus erythematosus Summary OMass Therapeutics closed…